defining platinium ineligible | ev-103 study by dr. jonathan rosenberg
Published 1 year ago • 89 plays • Length 0:49Download video MP4
Download video MP3
Similar videos
-
15:53
ev-103 study by dr. jonathan rosenberg led to the fda approval of enfortumab pembrolizumab
-
0:57
results of ev 103 | ev-103 study by dr. jonathan rosenberg
-
1:00
ev-103 cohort k study that led to the approval of enfortumab vedotin pembrolizumab
-
0:58
when to consider or not consider ev combination #oncology #lungcancer #cancer #2023
-
0:41
current standard of care in advanced bladder cancer #oncology #bladdercancer #lungcancer
-
3:20
latest ev-103 update further supports enfortumab for untreated advanced uc | jonathan rosenberg
-
3:07
ev-301 update reinforces third-line enfortumab vedotin benefit in advanced uc | jonathan rosenberg
-
0:34
pembrolizumab plus enfortumab vedotin for bladder cancer
-
1:05
biosimilar trastuzumab: a cost effective alternative for breast cancer treatment
-
2:18
jonathan rosenberg on enfortumab vedotin for urothelial carcinoma
-
2:03
dr. rosenberg on enfortumab vedotin/pembrolizumab in urothelial carcinoma
-
2:09
enfortumab vedotin for bladder cancer
-
1:08
case 2: cisplatin-ineligible metastatic bladder cancer
-
0:50
the addition of platinum compounds to standard chemotherapy for breast cancer patients
-
1:59
the immunoscore: a new way of stratifying cancer
-
1:00:41
basic and translational science in the time of the immune revolution in cancer
-
5:15
cancer immunotherapy: how it works, who will benefit with dr. steve rosenberg (part 1)
-
1:15
the co-evolution of the tumor and the tme under chemo- and immunotherapeutic selection pressures
-
1:56
dr. schwartzberg on the use of therapeutic biosimilars in breast cancer